Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?
Oettle
Helmut
H
Charité School of Medicine, Department of Medical Oncology and Hematology, Campus Virchow-Klinikum, Berlin 13353, Germany. helmut.oettle@charite.de
Hilbig
Andreas
A